Tolterodine
Detrol (IR) · Detrol LA (ER)
Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Overactive bladder with urge urinary incontinence, urgency, and frequency | Adults | Monotherapy | FDA Approved |
Tolterodine is an established first-line pharmacological option for adults with overactive bladder (OAB) who have not achieved adequate relief from behavioral and lifestyle interventions alone. It is available in both immediate-release and extended-release formulations. The extended-release form is generally preferred due to a lower incidence of dry mouth and once-daily convenience. Clinical trials have demonstrated significant reductions in urinary frequency, urgency episodes, and incontinence episodes compared with placebo (FDA PI).
Pediatric overactive bladder / enuresis: Tolterodine has been studied in children aged 5–10 years for OAB symptoms; however, FDA-approved pediatric studies did not demonstrate efficacy, and tolterodine is not approved for pediatric use. Evidence quality: Low.
Neurogenic detrusor overactivity (adults): Used in select patients with neurogenic bladder when first-line agents are not tolerated, though evidence is limited to small observational studies. Evidence quality: Low.
Dosing
Adult Dosing — By Clinical Scenario
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| OAB — extended-release, standard patient | 4 mg once daily | 4 mg once daily | 4 mg/day | Swallow capsule whole with water; do not crush or chew May reduce to 2 mg QD based on tolerability |
| OAB — immediate-release, standard patient | 2 mg twice daily | 2 mg twice daily | 4 mg/day | May take with or without food May reduce to 1 mg BID if poorly tolerated |
| OAB — patient on potent CYP3A4 inhibitor | ER: 2 mg QD; IR: 1 mg BID | ER: 2 mg QD; IR: 1 mg BID | ER: 2 mg/day; IR: 2 mg/day | Applies to ketoconazole, clarithromycin, itraconazole, ritonavir Mandatory dose reduction (FDA PI) |
| OAB — hepatic impairment (Child-Pugh A or B) | ER: 2 mg QD; IR: 1 mg BID | ER: 2 mg QD; IR: 1 mg BID | ER: 2 mg/day; IR: 2 mg/day | Child-Pugh C: tolterodine ER is not recommended Reduced hepatic clearance increases exposure |
| OAB — severe renal impairment (CrCl 10–30 mL/min) | ER: 2 mg QD; IR: 1 mg BID | ER: 2 mg QD; IR: 1 mg BID | ER: 2 mg/day; IR: 2 mg/day | CrCl <10 mL/min: not recommended (not studied) Higher drug concentrations observed in renal impairment |
The extended-release formulation delivers the same total daily active moiety exposure as the IR form (AUC equivalence) but with a substantially lower rate of dry mouth (23% vs 35%). Most clinicians start with ER 4 mg once daily unless cost or swallowing difficulty is a concern. If a patient cannot swallow capsules whole, switching to the IR tablet at 2 mg BID is an appropriate alternative.
Pharmacology
Mechanism of Action
Tolterodine is a competitive muscarinic receptor antagonist that blocks all five muscarinic receptor subtypes (M1–M5) without meaningful selectivity for any individual subtype in binding assays. Its clinical utility in overactive bladder arises from functional selectivity for the bladder detrusor muscle over salivary glands, a property attributed to the combination of parent drug and its equipotent active metabolite 5-hydroxymethyl tolterodine (5-HMT). By blocking M3-mediated acetylcholine signaling in the detrusor, tolterodine reduces involuntary bladder contractions, increases functional bladder capacity, and decreases the sensation of urgency. This translates into fewer micturitions per day, fewer urgency episodes, and reduced incontinence events. The functional bladder selectivity accounts for its improved dry mouth profile compared with older antimuscarinics such as oxybutynin.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | ≥77% absorbed; Tmax 1–2 h (IR), 2–6 h (ER); food increases IR bioavailability ~53% but does not affect active moiety | Rapid onset with IR; ER provides steady-state concentrations with once-daily dosing; food has no clinically relevant effect on overall activity |
| Distribution | Vd 113 L; protein binding ~96.3% (primarily to alpha-1-acid glycoprotein) | Extensive tissue distribution; high protein binding means free fraction may increase in hypoalbuminemia or conditions reducing alpha-1-acid glycoprotein |
| Metabolism | Extensive first-pass via CYP2D6 (to active 5-HMT) and CYP3A4 (N-dealkylation); bioavailability 17% (EM) vs 65% (PM) | CYP2D6 poor metabolizers have higher tolterodine levels but lower 5-HMT; total active moiety exposure similar between EM and PM — no routine genotyping needed |
| Elimination | t½ 2–3 h (EM), ~10 h (PM) for IR; ~77% urine, ~17% faeces as metabolites | Predominantly renal excretion of metabolites; dose reduction needed with CrCl 10–30 mL/min; avoid if CrCl <10 mL/min (not studied) |
Side Effects
The adverse effect data below are drawn from the pivotal phase 3 trials of both formulations. Incidence rates for the ER formulation are from a 12-week, placebo-controlled study of 505 patients on tolterodine ER 4 mg daily. Incidence rates for the IR formulation are from five phase 3 studies of 986 patients on tolterodine 2 mg BID (FDA PI).
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Dry mouth | 23% (ER) / 35% (IR) | Most frequently reported effect; severity mostly mild to moderate; severe in <2%; dose-dependent and often improves with continued use; the ER formulation substantially reduces the rate versus IR |
| Adverse Effect | Incidence (ER / IR) | Clinical Note |
|---|---|---|
| Headache | 6% / 7% | Typically mild and self-limiting; one of the leading causes of early discontinuation with IR |
| Constipation | 6% / 7% | Anticholinergic class effect; advise adequate fluid and fibre intake |
| Abdominal pain | 4% / 5% | Usually mild upper abdominal discomfort; not typically dose-limiting |
| Vertigo / Dizziness | 2% / 5% | More common with IR; warn patients about driving and operating machinery |
| Dyspepsia | 3% / 4% | May be managed by taking the drug with food |
| Fatigue | 2% / 4% | Usually transient; consider dose reduction if persistent |
| Somnolence | 3% / 3% | CNS antimuscarinic effect; exercise caution in elderly patients and those taking other sedatives |
| Dry eyes (xerophthalmia) | 3% / 3% | Antimuscarinic class effect; lubricating eye drops may provide relief |
| Abnormal vision | 1% / 2% | Accommodation difficulty; caution regarding driving at night |
| Sinusitis | 2% / — | Reported in ER trial; likely related to mucosal drying |
| Diarrhea | — / 4% | Reported in IR trials; paradoxical for an anticholinergic but occasionally observed |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Anaphylaxis / Angioedema | Very rare | First or subsequent doses | Discontinue immediately; emergency treatment; permanent discontinuation |
| QT prolongation | Rare (dose-dependent; more pronounced in PM) | Days to weeks | ECG monitoring if risk factors; avoid concomitant Class IA/III antiarrhythmics if possible; no Torsade de Pointes cases reported in post-marketing surveillance |
| Urinary retention | Rare | Days to weeks | Discontinue or reduce dose; catheterisation may be required; assess for bladder outlet obstruction |
| Confusion / Memory impairment / Hallucinations | Rare (post-marketing) | Days to months | Discontinue and evaluate; particularly monitor elderly patients and those on cholinesterase inhibitors |
| Tachycardia / Palpitations | Rare (post-marketing) | Variable | ECG assessment; dose reduction or discontinuation; evaluate cardiac risk |
| Reason for Discontinuation | Incidence | Context |
|---|---|---|
| Dry mouth | ER: 2.4%; IR: ~1% | Most common single AE cause; highest in first 4 weeks |
| Dizziness | IR: ~1% | Leading cause alongside headache in IR trials |
| Headache | IR: ~1% | Among most common reasons for early discontinuation with IR |
Dry mouth is the most clinically significant tolerability barrier. Practical interventions include sugar-free gum or lozenges, frequent small sips of water, a saliva substitute, and avoiding caffeine and alcohol. If dry mouth persists beyond 4 weeks at a severity that impairs quality of life, consider switching from IR to ER formulation, reducing dose, or transitioning to mirabegron (a beta-3 agonist with minimal anticholinergic effects). Persistent dry mouth increases the risk of dental caries and oral candidiasis, so dental hygiene should be reinforced.
Drug Interactions
Tolterodine undergoes extensive hepatic metabolism primarily via CYP2D6, with CYP3A4 serving as a secondary pathway. The key clinical interactions arise from inhibition of CYP3A4 (which increases tolterodine exposure in all patients) and from additive anticholinergic burden with co-prescribed agents. Tolterodine itself does not significantly inhibit CYP1A2, CYP2D6, CYP2C9, CYP2C19, or CYP3A4 at therapeutic concentrations and therefore has limited perpetrator potential.
Monitoring
-
Symptom Response
4–8 weeks after initiation, then q6–12 months
Routine Assess frequency of micturitions, urgency episodes, and incontinence events using a bladder diary. Evaluate patient-reported quality-of-life improvement. If inadequate response at 4–8 weeks, consider dose adjustment or alternative agent. -
Post-Void Residual
Baseline (if BPO risk), then as needed
Trigger-based Obtain post-void residual volume (via ultrasound) in patients at risk of bladder outlet obstruction (e.g., men with BPH) before starting tolterodine. Repeat if symptoms of incomplete emptying, weak stream, or acute retention develop. -
Renal Function
Baseline
Routine Measure serum creatinine and estimate CrCl before initiation. Dose reduction required for CrCl 10–30 mL/min; not recommended below 10 mL/min. -
Hepatic Function
Baseline
Routine Assess hepatic status before initiation. Dose reduction for Child-Pugh A/B; contraindicated in ER formulation for Child-Pugh C. Clinical hepatotoxicity is exceedingly rare. -
Cognitive Function
Ongoing in elderly
Trigger-based Monitor for confusion, memory impairment, or hallucinations, particularly in patients over 65 years, those with pre-existing cognitive decline, or those receiving other anticholinergic or CNS-active medications. Consider periodic cognitive screening. -
ECG (QTc)
Baseline if risk factors
Trigger-based Obtain baseline ECG in patients with known QT prolongation, on Class IA/III antiarrhythmics, or with significant electrolyte abnormalities. The QT effect is dose-dependent and more pronounced in CYP2D6 poor metabolizers. -
Anticholinergic Burden
At initiation and medication review
Routine Calculate total anticholinergic burden score using a validated tool (e.g., ACB Scale). Minimise concurrent anticholinergics, especially in older adults where cumulative burden is associated with cognitive decline and falls.
Contraindications & Cautions
Absolute Contraindications
- Urinary retention — antimuscarinic action worsens incomplete bladder emptying
- Gastric retention — reduced GI motility can precipitate or worsen gastric outlet obstruction
- Uncontrolled narrow-angle glaucoma — mydriatic effect may increase intraocular pressure and precipitate acute angle closure
- Hypersensitivity — known allergy to tolterodine or fesoterodine (which shares the active metabolite 5-HMT), or to any excipient
Relative Contraindications (Specialist Input Recommended)
- Severe hepatic impairment (Child-Pugh C) — ER formulation is specifically not recommended; IR requires specialist assessment of risk-benefit
- Severe renal impairment (CrCl <10 mL/min) — no studied data; use not recommended
- Clinically significant bladder outlet obstruction — risk of acute urinary retention; only prescribe after urological evaluation and with monitoring for post-void residual
- GI obstructive disorders — conditions such as pyloric stenosis or severe constipation may be worsened
Use with Caution
- Controlled narrow-angle glaucoma — may be used with ophthalmology follow-up
- Myasthenia gravis — anticholinergic agents may decrease cholinergic activity at the neuromuscular junction
- Known QT prolongation or electrolyte imbalance — QT effect observed at supratherapeutic doses; consider baseline ECG
- CYP2D6 poor metabolizers — higher parent drug exposure; QT effects more pronounced
- Elderly patients — increased vulnerability to CNS effects (confusion, falls, cognitive impairment); falls on the Beers Criteria list for potentially inappropriate medications in older adults
- Hot environments — reduced sweating due to antimuscarinic effects may impair thermoregulation
All antimuscarinic agents for OAB, including tolterodine, carry a class-wide concern for cognitive adverse effects in elderly patients. The American Geriatrics Society Beers Criteria lists antimuscarinics as potentially inappropriate in adults 65 years and older due to risk of confusion, delirium, and worsened cognitive function. Clinicians should weigh the benefits of symptom control against the cumulative anticholinergic burden, particularly in patients with or at risk for dementia. Non-anticholinergic alternatives such as mirabegron or vibegron should be considered in this population.
Patient Counselling
Purpose of Therapy
Tolterodine works by relaxing the bladder muscle to reduce the urge to urinate and prevent leaking accidents. It does not cure overactive bladder but manages symptoms alongside behavioural strategies such as timed voiding, pelvic floor exercises, and fluid management. Most patients notice improvement within 4 to 8 weeks of starting treatment. It is important to take the medication consistently at the same time each day.
How to Take
The extended-release capsule should be swallowed whole with water once daily — it must not be crushed, chewed, or opened. The immediate-release tablet is taken twice daily, with or without food. If a dose of the ER capsule is missed, the patient should skip the missed dose and take the next one at the usual time the following day; do not double up.
Sources
- Detrol LA (tolterodine tartrate extended-release capsules) — Full Prescribing Information. Viatris Specialty LLC. Revised 2022. DailyMed Primary source for ER dosing, adverse event incidence rates, pharmacokinetics, and drug interaction data used throughout this monograph.
- Detrol (tolterodine tartrate) Tablets — Full Prescribing Information. Pfizer Inc. Revised 2016. FDA Label Primary source for IR-specific dosing, adverse event Table 5, and pharmacokinetic parameters in extensive and poor metabolizers.
- Tolterodine tartrate extended-release capsules — Generic Prescribing Information. Teva Pharmaceuticals USA. Revised 2018. DailyMed Generic label confirming bioequivalence and identical adverse event profile to branded Detrol LA.
- Van Kerrebroeck P, Kreder K, Jonas U, Zinner N, Wein A. Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. Urology. 2001;57(3):414–421. doi:10.1016/S0090-4295(00)01113-4 Pivotal phase 3 trial comparing tolterodine ER 4 mg with IR 2 mg BID and placebo; established ER superiority for dry mouth reduction.
- Appell RA. Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis. Urology. 1997;50(6A Suppl):90–96. doi:10.1016/S0090-4295(97)00599-4 Pooled analysis of four 12-week RCTs establishing tolterodine efficacy versus placebo and favourable tolerability versus oxybutynin.
- Diokno AC, Appell RA, Sand PK, et al. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder (OPERA). Mayo Clin Proc. 2003;78(6):687–695. doi:10.4065/78.6.687 Head-to-head trial showing similar efficacy between tolterodine ER and oxybutynin ER with lower dry mouth rate for tolterodine (22.3% vs 29.7%).
- Gormley EA, Lightner DJ, Burgio KL, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline (2019 amendment). J Urol. 2019;202(3):558–563. doi:10.1097/JU.0000000000000309 Current AUA/SUFU guideline recommending antimuscarinics including tolterodine as second-line therapy after behavioural interventions.
- EAU Guidelines on Management of Non-Neurogenic Female Lower Urinary Tract Symptoms. European Association of Urology. Updated 2023. EAU Guidelines European guideline supporting antimuscarinics for OAB with caution regarding cognitive effects in older patients.
- American Geriatrics Society 2023 Updated AGS Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc. 2023;71(7):2052–2081. doi:10.1111/jgs.18372 Lists antimuscarinics as potentially inappropriate in adults ≥65 due to risk of cognitive impairment and delirium.
- Nilvebrant L, Hallen B, Larsson G. Tolterodine — a new bladder selective muscarinic receptor antagonist: preclinical pharmacological and clinical data. Life Sci. 1997;60(13–14):1129–1136. doi:10.1016/S0024-3205(97)00056-0 Foundational paper describing tolterodine’s functional bladder selectivity and the pharmacological basis for its improved tolerability profile.
- Brynne N, Stahl MMS, Hallen B, et al. Pharmacokinetics and pharmacodynamics of tolterodine in man: a new drug for the treatment of urinary bladder overactivity. Int J Clin Pharmacol Ther. 1997;35(7):287–295. PMID: 9247843. Characterised tolterodine PK in extensive and poor CYP2D6 metabolizers, establishing the clinical irrelevance of metabolizer status on total active moiety exposure.
- Hills CJ, Winter SA, Balfour JA. Tolterodine. Drugs. 1998;55(6):813–820. doi:10.2165/00003495-199855060-00007 Comprehensive drug review covering PK in special populations including hepatic and renal impairment, informing dose adjustment recommendations.
- Olsson B, Szamosi J. Multiple dose pharmacokinetics of tolterodine in healthy volunteers. Biopharm Drug Dispos. 2001;22(1):1–9. doi:10.1002/bdd.249 Detailed PK data including Tmax, half-life, protein binding, and volume of distribution referenced in the ADME table.